PALO ALTO, Calif., Jan. 4 /PRNewswire/ -- Genencor International, Inc.
(Nasdaq: GCOR) today announced that it will present at the JPMorgan H&Q 20th
Annual Healthcare Conference at 3:30 p.m. (PST) on Monday, January 7, 2002, at
the Westin St. Francis Hotel in San Francisco, California.
W. Thomas Mitchell, chairman and chief executive officer, will present at
3:30 p.m., PST. The presentation, which will contain an update on the
company's progress in the health care market, is scheduled to be webcast live
and may be accessed through Genencor's website http://www.genencor.com or
through the JPMorgan H&Q website at http://www.jpmhq.com. The webcast will
also be archived on Genencor's website until close of business on January 14.
About Genencor
Genencor International is a diversified biotechnology company that
develops and delivers innovative products and services for the health care and
bioproducts markets. Using an integrated set of technology platforms,
Genencor's products deliver innovative and sustainable solutions to many of
the problems of everyday life.
Genencor was established in 1982 as a joint venture between Genentech Inc.
and Corning Incorporated. Since its founding, Genencor has grown to become a
leading biotechnology company, with over $315 million in year 2000 annual
revenues and more than 3,400 owned and licensed patents and applications.
Genencor has principal offices in Palo Alto, California; Rochester, New York;
and Leiden, the Netherlands.
This press release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. These include statements
concerning plans, objectives, goals, strategies, future events or performance
and all other statements which are other than statements of historical fact,
including without limitation, statements containing words such as "believes,"
"anticipates," "expects," "estimates," "projects," "will," "may," "might" and
words of a similar nature. Such statements involve risks and uncertainties
that could cause actual results to differ materially from those projected.
Some important factors that could cause actual results to differ include
significant fluctuations in product performance depending on factors such as a
dependence on the efforts of third parties, new and uncertain technology
employed by Genencor and its uncertain application to new business ventures,
failure to develop products for the health care markets, inability to complete
certain transactions and realize anticipated benefits from acquisitions,
dependence on intellectual property rights, the competitive nature of
Genencor's industry and risks of obsolescence of certain technology. These and
other risk factors are more fully discussed in Genencor's most recent Annual
Report on Form 10-K or Quarterly Report on Form 10-Q filed with the United
States Securities and Exchange Commission. The forward-looking statements
contained in this release represent the judgment of Genencor as of the date of
this release. Genencor disclaims, however, any intent or obligation to update
any forward-looking statements.
FOR MORE INFORMATION CONTACT:
Angela Blackwell, +1-716-256-6973
Bella Ling, +1-650-846-7676
SOURCE Genencor International, Inc.
 back to top
Related links:
http://www.genencor.com
http://www.jpmhq.com
CONTACT:
Angela Blackwell, +1-716-256-6973, or Bella
Ling, +1-650-846-7676, both of Genencor International, Inc.
|
